BioCentury | Oct 6, 2020
Emerging Company Profile

Scribe: engineering CRISPR’s next generation

Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts. Scribe Therapeutics Inc....
BioCentury | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

Pfizer is hoping that discounts of 22-24% from reference drugs’ wholesale acquisition costs (WACs) will help it gain market share for three new or soon-to-be launched biosimilars, each of which will compete with at least...
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...Now, we’re in a different age.” These early therapies include the yttrium 90-labeled anti-CD20 mAb Zevalin...
...copper 67 and yttrium 90 -- have a longer clinical history going back to the Zevalin...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

Ten years after the U.S. created a pathway for biosimilars--and four and a half years after the first FDA approval--a few manufacturers have demonstrated that they can overcome the technical, regulatory and commercial barriers to...
BioCentury | Oct 9, 2019
Politics, Policy & Law

Long-term data help two drugs sway ICER in drug price report

An analysis by the Institute for Clinical and Economic Review of price increases for some of the costliest drugs in the U.S. has found that seven of nine were not supported by new clinical evidence,...
BioCentury | Aug 23, 2019
Clinical News

Aug. 22 Clinical Quick Takes: Rituximab biosimilar meets endpoint; plus Aimmune, NKMax, Calibr

Rituximab biosimilar meets NHL endpoint Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said top-line results from the Phase III JASMINE study showed rituximab biosimilar (ABP 798) met the trial's primary endpoint of clinical equivalence to...
BioCentury | Aug 22, 2019
Distillery Techniques

Delivering mAbs to CNS metastases using polymer-based nanoparticles

TECHNIQUES CATEGORY: Drug delivery TECHNOLOGY: Polymers; nanoparticles A zwitterionic polymer-based nanoparticle system could enable delivery of therapeutic mAbs to cancer metastases in the CNS. The method involves encapsulating mAbs in nanoparticles formed by cross-linking methacryloyloxyethyl...
BioCentury | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
BioCentury | Jun 13, 2019
Company News

June 12 Company Quick Takes: Macao approves Zai's Zejula; plus Roche, NIH, CVS and Dassault-Medidata

Zai obtains Zejula's approval in Macao Zai Lab Ltd. (NASDAQ:ZLAB) said it has received approval in Macao to market PARP inhibitor Zejula niraparib to treat ovarian cancer. Zai holds its local rights from the Tesaro...
BioCentury | Mar 22, 2019
Company News

Roche gets European approval of rituximab to treat skin disease

Roche said the European Commission approved MabThera rituximab to treat pemphigus vulgaris (PV). FDA approved the drug for the indication in June 2018. Genentech Inc. and Biogen Inc. (NASDAQ:BIIB) co-market IV rituximab in the U.S...
Items per page:
1 - 10 of 3784